AZN Share PerformanceMore
|52 week high||5,520.0 22/06/17|
|52 week low||3,996.0 06/12/16|
|52 week change||635.0 (14.63%)|
|4 week volume||45,487,111 25/10/17|
Latest News« previous» nextMore
16/11/2017 - 08:30 StockMarketWire
HSBC today reaffirms its reduce investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 4380p (f...
15/11/2017 - 09:35 StockMarketWire
AstraZeneca and its global biologics research and development arm, MedImmune, have announced that the US Food and D...
15/11/2017 - 07:00 RNS
RNS Number: 5114W AstraZeneca PLC 14 November 2017 This announcement contains inside information 14 November 2017 22:45 GMT FASENRA (BENRALIZUMAB) RECEIVES US FDA APPROVAL FOR SEVERE EOSINOPHILIC ASTHMA Fasenra distinctively targets and rapidly depletes eosinophils and is the first respiratory biologic with an 8-week maint...
10/11/2017 - 13:06 StockMarketWire
AstraZeneca has confirmed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicin...
10/11/2017 - 11:35 RNS
RNS Number: 1876W AstraZeneca PLC 10 November 2017 This announcement contains inside information 10 November 2017 11:35GMT BENRALIZUMAB RECEIVES POSITIVE EU CHMP OPINION FOR SEVERE, UNCONTROLLED EOSINOPHILIC ASTHMA Benralizumab uniquely targets and rapidly depletes eosinophils and is the first respiratory biologic w...
09/11/2017 - 08:37 StockMarketWire
The FTSE 100 edged down 2.81 points to 7,527.09 on Thursday morning after trading on Wall Street was held back by conce...
09/11/2017 - 07:11 StockMarketWire
AstraZeneca's reported operating profits rose to $1,149m in the third quarter - up 12% on an actual basis and 9% at constant...
09/11/2017 - 07:00 RNS
RNS Number: 9871V AstraZeneca PLC 09 November 2017 AstraZeneca PLC 9 November 2017 07:00 Year-To-Date and Q3 2017 Results An improved sales performance as the pipeline-driven transformation gathered pace Financial Summary YTD 2017 Q3 2017 $m % change $m % change Actual CER 1 Actual CER Total Revenue 16,688 (4) (3) 6,232 9 10 Product Sales 14...
Latest discussion posts More
“"When Equilibrium's Mike Deverell built our Long-Term Growth portfolio in the spring, he was cautious about the stockmarket. Holly Black reports on what's changed since.With ...”▼
“"Thirty years ago, the notion of robots replacing humans was the vision of dystopian science fiction. However, huge technological advances since then mean that 'intelligent' ...”▼
“The FDA grants accelerated approval for AstraZeneca's (AZN +0.9%) BTK inhibitor Calquence (acalabrutinib) for the treatment of adult patients with mantle cell lymphoma who have ...”▼
Codes & Symbols
|Symbols||AZN, LSE:AZN, AZN.L, AZN:LN, LON:AZN, XLON:AZN|
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment